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Summary The present study was undertaken to compare the relationship between response to exogenous
epidermal growth factor (EGF) and the expression of the EGF-receptor (EGF-R) in an androgen sensitive
(LNCaP) and insensitive (DU145) prostate cancer cell line. Although both cell lines demonstrated a single
EGF-R binding site of similar high affinities (mean dissociation constant (Kd) ± S.D. for DU145 = 1.0 ± 0.6
nmol 1-'; LNCaP = 2.8 2.2 nmol 1') the number of binding sites (RT) for the hormone insensitive DU145
cells (mean ± S.D. = 2.5 1.0 x 105 sites/cell) and 10-fold greater than that expressed in the androgen respon-
sive LNCaP cell line (mean ± S.D. = 2.0 ± 1 x 104 sites/cell). Additionally exogenous EGF only minimally
affected the growth and DNA synthesis of DU145 cells whereas LNCaP cells showed a significant response
which was dose dependent. The autologous production of EGF-like molecules by DU145 cells is believed to
reduce the cells needs for exogenous mitogens, thereby rendering the cells autostimulatory. Treatment of
LNCaP cells with Mibolerone - a synthetic androgen - did not affect either the expression of the EGF
receptor or the proliferative response observed with EGF. Western blot analysis, using monoclonal antibodies
directed against the EGF receptor revealed a band of approximately 170 kD with DU145 cell lysates but the
LNCaP EGF receptor was not detected using this technique.
In the early stages, prostate cancer growth is almost always
androgen dependent, but eventually the tumour progresses to
a more aggressive state in which growth is androgen indepen-
dent (Griffiths et al., 1987). This transition is a major ob-
stacle to successful treatment not only of carcinoma of the
prostate but also in many other tumours originating from
hormone responsive tissues (Hodges, 1979; Lippman, 1984).
The role of EGF and its receptor as a mediator of prostate
cancer cell growth has in recent years come under intense
investigation. Many workers are now coming to recognise
growth factors as playing a major role in the progression of
androgen dependent to androgen independent prostate
cancer cell growth, though the evidence in the literature
remains contradictory and no clear pattern is emerging:
Initially the expression of EGF receptor messenger RNA was
demonstrated in the androgen independent PC3 human pros-
tate cancer cell line (Derynck et al., 1987) but subsequently
the presence of EGF-R was also confirmed in the androgen
sensitive LNCaP cells (Schuurmans et al., 1988). However,
the evidence for the modulation of EGF-R by androgen is
not conclusive and whether the steroid hormone up regulates
(Schuurmans et al., 1988) or down regulates (Traish &
Wotiz, 1987; St-Arnaud et al., 1988) the EGF-R varies and
depends on the type of experiments carried out. Further-
more, the response may also reflect the species from which
the prostate cells were derived (Schuurmans et al., 1988;
Traish & Wotiz, 1987; St-Arnaud et al., 1988). This complex
relationship between steroid hormone and growth factors is
not exclusive to the prostate gland, but has been observed in
other hormone dependent organs. In breast cancer where a
detailed study has been carried out on the interaction
between oestrogens, progestins and growth factors and how
they may act together to regulate cell proliferation, oestro-
gens have been shown to affect the production of TGF-(x
(Dickson et al., 1986), and suppress the secretion of inhibi-
tory growth factors (Knabbe et al., 1987) whereas progestins
modulate epidermal growth factor receptor expression
(Murphy et al., 1986).
Although the evidence for steroid hormone regulation of
growth factor content and activity in breast cancer is con-
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vincing there are also suggestions that the progession to
oestrogen independent breast cancer cell growth may be the
result of a change in the activity of the growth factor or its
receptor (King, 1990) and this highlights, once again, the
complex nature and multiple pathways by which steroid hor-
mone sensitive cells might be regulated by steroids. To fur-
ther our understanding of the role of EGF, its receptor, and
its regulatory function in endocrine responsive and unrespon-
sive prostate cancer, we have compared two human prostate
cancer cell lines, the androgen insensitive DU145 cell line and
the androgen sensitive LNCaP cell line and studied response
to exogenous EGF and the expression of the EGF receptor.
Moreover, the role of androgens in modulating growth factor
receptor expression and growth rate is also investigated.
Materials and methods
Growthfactors and hormones
Epidermal growth factor from mouse submaxillary gland
(mEGF; receptor and tissue culture grade) was purchased
from Collaborative Research (Universal Biologicals Ltd., St
Ann's Road, London). Rat transforming growth factor alpha
(rTGFa) was kindly donated by Dr H. Gregory, ICI,
Macclesfield, UK. The synthetic androgen 7a, 17a-dimethyl-
19-nontestosterone (DMNT;Mibolerone) was purchased from
Amersham International plc, Berks, UK.
Monoclonal antibodies
The mouse MAb F4 was kindly donated by Dr W. Gullick,
Department of Oncology, Hammersmith Hospital, London,
UK. The MAb was produced to a synthetic peptide consist-
ing of residues from the cytoplasmic domain of the EGF
receptor (Gullick et al., 1986).
Cell culture
The cell lines DU145 and LNCaP were used in all experi-
ments. DU145 was obtained from Dr D.D. Mickey, Depart-
ment of Urology, University of North Carolina, Chapel Hill,
USA. DU145 is a long-term culture cell line derived from a
human prostatic adenocarcinoma metastatic to brain
(Mickey et al., 1980). The cells arrived at the 50th passage
and were immediately subcultured and cells between passage
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numbers 60-70 were used for all experiments. The LNCaP
cell line (derived from a fast growing colony, FGC) was
kindly donated by Dr C. Eaton, Tenovus Institute, Cardiff,
Wales. The LNCaP cell line was originally derived from a
lymph node carcinoma of the prostate. The cells used in this
study were a subline of the original parent LNCaP (Horos-
zewicz et al., 1983). This subline is similar to its parent line
and differs only in growth rate. Cells from passage numbers
75-85 were used for all experiments in this investigation.
The cells were maintained at 37°C in a humidified atmo-
sphere of 95% air and 5% CO2 in 75cm2 tissue culture flasks
(Corning, Staffordshire, UK). DU145 cells were routinely
maintained in serum free media (SFM) which consisted of
RPMI 1640 (Flow Laboratories, Irvine, UK) supplemented
with serum free constituents (10 mg I` of insulin, 10 mg I`
of transferrin, 50tLg I` of phosphoethanolamine, 0.04 nmol
I` of 3,3',5-triiodo-thyronine, 1 mg 1` of hydrocortisone;
Sigma Chemicals, Dorset, UK, 1 ml 1' of trace element mix;
Gibco, Irvine, UK, 1% of L-glutamine, 100 units ml' of
penicillin and 100figmlm' of streptomycin). The cell line
LNCaP was routinely cultured in complete medium (RPMI
1640 supplemented with 10% foetal calf serum (FCS); Gibco,
1% of L-glutamine, 100 units ml' of penicillin and 100 fg
ml1' of streptomycin) as these cells adhere loosely to the
culture vessels in SFM. However all growth and receptor
binding experiments were carried out in SFM after plating in
complete medium.
Cellproliferation
Subconfluent DU145 cell monolayers were rinsed in sterile
Dulbecco 'A' phosphate-buffered saline (Dulbecco 'A' PBS;
Oxoid Ltd, UK) and once with 0.25% trypsin and 0.02%
EDTA (Gibco). The cells were then incubated for 5 min at
37°C and subsequently resuspended in SFM supplemented
with 0.5% FCS; FCS was added to the SFM to facilitate
plating. The cells were then plated in 6 well plates (9.6 cm2;
cell-cult), at a density of 2 x I05 cells/well. EGF (0.01-10
nmoll1'; tissue-culture grade) was then added 24h later in
SFM to the plated cells for up to 6 days, with medium
changes on alternate days; control wells received no EGF.
After this period the cells were harvested with trypsin and
counted using the Trypan Blue-exclusion method.
Subconfluent LNCaP cell monolayers from 75 cm2 tissue
culture flasks were washed once with Dulbecco 'A' PBS and
once with a 0.08 mol 1' solution of sodium citrate. The cells
were then subsequently resuspended in complete medium and
plated in six well plates at a density of 2 x I04 cellscm2.
For growth and receptor binding studies cells were plated in
complete medium after 3 days were washed with Dulbecco
'A' PBS before the addition of SFM, which was left in
contact with the cells for approximately 8 h. After this time
EGF (0.01-10nmoll1') and/or Mibolerone (0.1 nmoll1')
was added in SFM to each well with control wells receiving
no growth factor or androgen. The medium was changed
after 3 days and on the 6th day the cells were harvested with
trypsin and counted.
The stock solution of Mibolerone was made up in 100%
ethanol, but less than 0.1% ethanol was added to LNCaP
cell cultures.
3H-Thymidine incorporation
Subconfluent DUI45 and LNCaP cells from 75cm2 tissue
culture flasks were disrupted and plated as described for cell
proliferation experiments. DU145 cells were plated at a den-
sity of 1 x I04 cells/well and LNCaP cells at a density of
2 x I04 cells cm-2 in 96 well plates (0.32 cm2). After plating
the cells, EGF (0.001-1Onmol 1') was added in SFM for
24 h, an optimal time point (MacDonald et al., 1990), with
control wells receiving no EGF. In some experiments Mibo-
lerone (0.1 nmol l- 1) was added with or without EGF to
LNCaP cells. After the incubation period (Methyl-3H) thymi-
dine (specific activity 74 GBq mmol-' (Amersham Interna-
tional plc, Berks, UK; 37 KBq/well) was added in RPMI for
at least 4 h. The medium in each well was aspirated and
resuspended before the addition of 10% ice-cold trichloro-
acetic acid (TCA). The precipitable cellular material was
harvested (Skatron Combi Cell harvester; Skatron, Norway)
2 h later on to filter mats by washing the wells 3 x in water
and then drying the filter mats at 60°C for 30 min. Each disc
of filter paper containing the dried precipitable cellular
material was then counted in scintillation fluid.
EGF radioreceptor assay
Binding assays were carried out on DU145 and LNCaP
monolayers in 24 well plates at a density of 2 x 105 cells/well.
Before addition of the binding medium the cells and binding
media were cooled on ice to inhibit receptor internalisation.
The cell monolayers were then gently washed with Dulbecco
'A' PBS and binding was initiated upon the addition of the
appropriate concentration of 1251I-EGF (specific activity
4 GBq jtg-1; Amersham International plc) in 0.5 ml of RPMI
1640. Non-specific binding was determined in the presence of
100-fold excess unlabelled EGF (receptor-grade). After incu-
bation at 4°C for 4 h (DU145), unbound was separated from
bound 251I-EGF by aspirating the contents of each well and
washing the cells 3 x with ice-cold Dulbecco 'A' PBS (0.5 ml
well). The cells were subsequently solubilised with 1 ml of
0.5 N sodium hydroxide, for 15 min at room temperature and
the dissolved cells transferred to plastic tubes for counting in
a gamma counter. LNCaP cell monolayers were incubated
for 6 h at 4°C and unbound was separated from bound
'25I-EGF by firstly aspirating off the medium containing the
radioligand and then adding 1 ml of ice-cold Dulbecco 'A'
PBS. The cells were resuspended by pipetting several times,
transferred to disposable plastic centrifuge tubes and subse-
quently pelleted for 10min at 1,500r.p.m. The supernatant
was aspirated, and the radioactivity of the cell pellets
measured in a gamma counter.
In view of the fact that mouse EGF and human EGF
(urogastrone) are equally effective in competing with 12511
EGF for EGF binding sites on DU145 and LNCaP cells
(data not shown), all receptor assay studies were performed
with the mouse derived ligand.
Specific binding was calculated as the difference between
total binding and non-specific binding. For all binding
experiments cell numbers were determined from control wells
(triplicate) in which only RPMI 1640 was added.
Saturation and competition analysis
Evaluation of binding parameters were obtained by satura-
tion analysis over the range 0.02-10 nmol 1' '25I-EGF with
or without excess unlabelled EGF. The dissociation constant
(Kd) and the number of binding sites (RT) were also measur-
ed by competition analysis with increasing concentrations of
EGF (0.01-300 nmol 1-') and a constant amount of 1251_
EGF (2 nmol I-l).
Saturation analysis ofandrogen treated LNCaP cells
The synthetic androgen Mibolerone (0.1 nmol 1-) was added
to LNCaP cell monolayers for a period of 6 days. After this
period, increasing doses of '25I-EGF (0.05-1Onmol 1') were
added to triplicate wells with or without excess unlabelled
EGF. The Kd and RT values were evaluated for androgen
treated and untreated LNCaP cells using the computer pro-
gram LIGAND as detailed subsequently.
Detection ofthe EGF receptor and the v-erbB gene product by
Western blotting
Cell monolayers (5 x 107 cells) were washed with Dulbecco
'A' PBS and pelleted by gentle centrifugation (5 min at 1,500
r.p.m.). The cell pellet was then lysed with 2 ml of 50 mmol
1' Tris-HCI buffer, pH 7.4, containing 1% v/v of Triton
X-100, 150 mmoll' of NaCl, 25 mmol -' of Benzamidine,
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ride, 1 mmol I` of dithiothreitol and 10% of glycerol and
centrifuged at 3,000 r.p.m. for 30 min. Sample buffer (400 "l)
containing P-mercaptoethanol was added to the soluble cellu-
lar material (100 Jl), the samples heated to 100°C for 3 min
and electrophoresed on 7.5% polyacrylamide gels containing
sodium dodecylsulphate.
After blotting on to a nitrocellulose membrane the strips
were blocked with 5% (w/v) skimmed milk solution for
10 min at room temperature, rinsed in washing buffer
(50mmoll'- of Tris, 150 mmoll1 of NaCl, 2mmoll' of
EDTA at pH 7.5) and incubated with MAb F4 (2 pg), with
2% BSA in washing buffer, for 2 h with continual shaking at
room temperature. A mouse MAb, raised against MHC IgG
class 2 was used as a non specific control. The strips were
then rinsed in washing buffer and incubated with alkaline
phosphatase antibody conjugate mouse IgG (Sigma) for 2 h
at room temperature. The strips were rinsed once more in
washing buffer and developed by the addition of Naphthol-
phosphate (15 mg Naphthol -AS-MX-phosphate (free acid)
in 1.5 ml dimethylformamide, added to 75 ml saline/0.05 mol
1-l Tris, pH 8.8 with 75 mg Fast Red TR salt; Sigma. The
development of the colour product was terminated by rinsing
in water.
Data analysis
The computer analysis employed for competition and satura-
tion was the weighted, nonlinear least-squares curve fitting
program LIGAND (DeLean et al., 1978; Munson & Rod-
bard, 1980), run on an IBM-PC. Data were analysed accord-
ing to a model for one or two binding sites. A model for two
binding sites is retained only when it fits the data significantly
better (P<0.05 partial F test) than a model for a single
binding site.
Statistical significance in the growth experiments was deter-
mined using a two-tailed Student's t-test for comparison of
means.
Results
Characterisation ofEGFbinding sites
To examine for the presence of specific EGF-R on the cell
surface of the DUI45 and LNCaP cells, increasing concen-
trations of '25I-EGF saturated receptor binding sites on
DUI45 and LNCaP cell monolayers, indicating specific bind-
ing of '25I-EGF, Figures la and b). The data for DUI45 were
analysed using the curve fitting program LIGAND and fitted
significantly to one class of binding site (P<0.05), with an
estimated Kd ± S.D. value of 1.0 ± 0.5 nmol 1-'. The number
of binding sites/cell ± S.D. was calculated as 2.0 x 105 ± 8 x
104. The dissociation constant ± S.D. of the EGF receptors
in LNCaP cells was calculated as 2.9 ± 2.2 nmol 1' and the
number of receptor binding sites/cell ± S.D. as 2.5 ± 1.3 x
104; almost 10-fold lower than DUI45 cells.
Overall the dissociation constant and binding capacity for
DU145 monolayers were 1.0 ± 0.6 nmol 1' and 2.5 ± 1 x 105
sites/cell respectively. The number of binding sites for
LNCaP cells was considerably less (2.0 ± 1 x 104). The dis-
sociation constant of 2.8 ± 2.2 nmol I` was lower overall,
but was not significantly different from DUI45 cells
(P<0.05).
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Figure 1 Saturation curves of DU145 and LNCaP cell lines.
Increasing dose of '25I-EGF (0.01 -10 nmol 1-') were incubated in
triplicate wells with or without a constant amount of unlabelled
EGF (200 nmol 1 ') for 4 h (DU145; Figure la) or 6 h (LNCaP;
Figure lb) at 4'C. DU145 monolayers were washed 3 x with
Dulbecco 'A' PBS to separate bound '251I-EGF from free 1251I
EGF, the cells were subsequently dissolved in 0.5 N NaOH and
the radioactivity remaining was evaluated. LNCaP monolayers
were pelleted, spun and the remaining radioactivity measured.
The dissociation constant and the number of EGF binding sites
were determined by the binding program LIGAND. Ten satura-
tion curves were analysed from DU145 and six from LNCaP
cells.
Table I Effect of Mibolerone on the affinity and binding capacity of
LNCaP EGF receptors
Mibolerone No Mibolerone
Kd mol I' 3.5 2.6 nM (3) 2.8± 1.8 nM (3) R sites/cell 2.0 1.1 x 104 2.5± 1.3 x 104
Mibolerone (0.1 nmol Il') was added in SFM to LNCaP cell
monolayers(2 x 104cell cm-2)inmultiwellplates foraperiodof6days.
Control wells were grown without Mibolerone. After 6days, saturation
analysis was performed with increasing concentrations of '25I-EGF
(0.01-10 nmol 1I') and a constant amount ofunlabelled excess ligand
(200 nmol/EGF). The affinity constant Kd and the number ofbinding
sites/cell (R) were calculated using the binding program LIGAND and
expressed as mean + S.D.; number of experiments are in parenthesis.
Saturation analysis ofmibolerone treated LNCaP cells
The effect of exposure of LNCaP cell monolayers to Mibo-
lerone for 6 days is shown in Table I. Neither the dissocia-
tion constant nor the number of EGF binding sites was
significantly altered by Mibolerone (P<0.05).
Expression ofthe EGF by Western blotting
The expression of the EGF receptor from DUI45 and
LNCaP cell lysates was demonstrated by Western blotting
(Figure 2). Incubation of DU145 cell lysates with the mono-
clonal F4, revealed a distinct band corresponding to a mole-
cular weight of 170,000 on SDS-PAGE (track 1), but there
was no band at 68 kDa (track 1). Neither the EGF receptor
nor the cytoplasmic domain of the receptor were observed
from LNCaP cell lysates using Western blotting (not shown).
Effect ofEGF on cellgrowth
The results depicted in Figures 3a and b demonstrate the
impact ofincreasing concentrations of EGF on the growth of
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Figure 2 Expression of the EGF receptor and the truncated
EGF receptor by Western blotting. Cell lysates (5 x 107 cells)
from DU145 and LNCaP cells were electrophoresed, blotted on
to nitrocellulose and incubated with the antibody F4 (track 1)
and a non-specific control (track 2). LNCaP results are not
shown.
the cell lines DU145 and LNCaP. An incremental trend in
DU145 cell growth was apparent with increasing concentra-
tions of EGF, with a 12% ± 12 maximum in cell number at
an EGF concentration of 0.3 nmol 1', but this stimulatory
trend was not significantly different from control values
(P> 0.05). Concentrations greater than 3.0 nmol 1' inhibited
proliferation in a dose-dependent manner with 10 nmol 1'
inhibiting cell proliferation by 17% ± 22; (Figure 3a).
In contrast to EGF's effect on DU145 proliferation,
LNCaP cell numbers were significantly increased. EGF exert-
ed a biphasic effect on proliferation with concentrations up
to 0.3 nmol I` enhancing proliferation by 98% ± 6 relative
to control values (P<0.001) and higher concentrations
abolishing this stimulatory effect (Figure 3b).
Effect ofEGF on 3H-thymidine incorporation
In a parallel study the impact of EGF on 3H-thymidine
incorporation was investigated (Figures 4a and b). After
24 h, EGF stimulated 3H-thymidine incorporation in DU145
cells in a dose dependent manner, with maximum incorpora-
tion observed at an EGF concentration of 1 nmol I`
(26% ± 13; P<0.001).
EGF also stimulated DNA synthesis in LNCaP cells in a
dose dependent fashion, with the maximal effect observed
with 0.3 nmol 1` of EGF; increasing 3H-thymidine incor-
poration by 78 ± 10% (P<0.001). Furthermore a dose-
dependent decrease in 3H-thymidine incorporation was noted
with concentrations greater than 0.3 nmol 1' (Figure 4b).
Effects ofEGF and Mibolerone on cell growth and
3H-thymidine incorporation
The androgen sensitive LNCaP cell line was used to investi-
gate the relationship between growth factors and androgens
in prostate cancer. The synthetic androgen Mibolerone was
0.001 0.01 0.1 1 10
EGF concentration (nmol -1)
Figure 3 Dose-response effect of EGF on cell proliferation of
DU145 and LNCaP cells in SFM. Cells in the exponential phase
of growth were seeded in six well plates at a density of 2 x 105
cells/well (DU145) or 2 x I04 cells cm 2 (LNCaP). After 24 h
EGF (0.01-10 nmol 1-') was added in SFM to serum free cul-
tures of DU145 cells for 6 days (Figure 3a). LNCaP cells were
plated with 10% FCS and after 3 days the cells were washed once
with Dulbecco 'A' PBS, SFM was added for several hours and
was subsequently replaced by fresh medium with EGF (0.01-10
nmol 1-1) for a period of 6 days (Figure 3b). The data are
expressed as mean percentages ± S.D. (n = 12; DU145 and n = 9;
LNCaP) of the untreated control, where the control is 100%.
added to SFM cultures of LNCaP cells with and without
EGF, for a period of 6 days and the cells counted after this
time (Figure 5a) or for 24 h and incorporation of 3H-thymi-
dine measured (Figure 5b).
EGF and Mibolerone independently increased cell prolifer-
ation by 82% ± 18 (P<0.001) and 51% ± 8.5 (P<0.02)
respectively. However the stimulation in thymidine incor-
poration following the addition of EGF was less than the
recent increase in cell number (98% ± 6) but this difference
may simply reflect the statistical variation of the systems
used. The addition of EGF and Mibolerone together to
LNCaP cells did not produce a greater stimulatory effect
than EGF alone (77% ± 12); that is the effect on prolifera-
tion was not additive (Figure 5a). A similar effect was
observed on DNA synthesis; EGF and Mibolerone indepen-
dently stimulated DNA synthesis by 80% ± 10 and 70 ± 14%
respectively (P<0.001). However, this response was not
additive as EGF and Mibolerone added together did not
increase 3H-thymidine incorporation above 79% ± 8 (Figure
Sb).
Discussion
In this study the comparison of the prostatic cancer cell lines
DU145 and LNCaP provided a useful in vitro model for the
study of EGF receptor expression and the mitogenic effect of
EGF in prostatic cancer in an androgen-responsive and
androgen-unresponsive state.
Competition and saturation analysis revealed that both cell
lines possess EGF receptors with one high affinity binding
site, consistent with the earlier findings for LNCaP cells
(Schuurmans et al., 1988) and DU145 cells (Wilding et al.,
1989) although other studies (Connolly & Rose, 1989)
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Figure 4 Dose-response effect of EGF on 3H-thymidine incor-
poration of DU145 and LNCaP cells. DU145 cells (1 x 104 cells/
well) were plated overnight in SFM/0.5% FCS in 96 well plates.
EGF (0.001-Onmol -') was added in SFM (six replicates/EGF
concentration) for 24 h. 3H-thymidine (37 Bq/well) was then add-
ed for 4 h, and the cells were trypsinised in 10% ice-cold TCA.
The cells were then harvested on to filter mats, dried and counted
in scintillation fluid. Each data point represents the mean ± S.D.
(n = 60) of ten separate experiments and the data are normalised
relative to the untreated SFM control (100%). LNCaP cells were
seeded at innocula of 2 x 104 cells cm 2 in 96 well plates in
complete medium. After 3 days EGF (0.01-10 nmol 1-') was
added in SFM for a period of 24 h. The experiment was then
carried out as for DU145. Each data point represents the mean ±
S.D. (n= 24) of three separate experiments and the data are
normalised relative to the untreated SFM control (100%).
observed two high affinity binding sites for DU145 cells
(KD = 8 x 10-10 and 1.1 X 10-9 M). In the present study,
binding data of DU145 cells were also analysed by a Scat-
chard plot, and one binding site for EGF was consistently
found. Therefore, it is unlikely that DU145 cells possess
more than one binding site for EGF.
Although the binding constants from both cell lines were
similar, a striking difference was observed between the
numbers of receptors expressed by these cells, with DU145
cells maintaining a 10-fold increase over the LNCaP cells.
These findings were also verified by Western blotting where
the EGF receptor was visualised from DU145 cell lysates and
not from LNCaP cell lysates. Similar patterns were observed
in EGF receptor expression between oestrogen-responsive
and oestrogen-unresponsive breast cancer cell lines (Davidson
et al., 1987). Oestrogen-responsive breast cancer cell lines
express relatively low numbers of EGF receptors whilst
oestrogen-unresponsive cells express higher EGF receptor
numbers. The correlation between EGF receptor expression
and endocrine status implies that steroid hormones might
influence the response to growth factors, by altering growth
factor receptor expression. However, the nature of the
interaction between androgens and EGF in prostate cancer
remains unclear since the results reported in this study
demonstrate that androgens do not modulate EGF receptor
expression. The steroidal androgen Mibolerone did not affect
either the level of receptors expressed or the affinity of the
receptor, contradicting the earlier studies (Schuurmans et al.,
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Figure 5 The effect of EGF and Mibolerone on cell proliferation
and DNA synthesis of LNCaP cells. Cells were seeded at inno-
culum of 2 x 104 cells cm-2 in six well plates or in 96 well plates.
After 3 days the factors to be tested were added in SFM as
indicated, for 6 days and the cells subsequently counted (left) or
3H-thymidine incorporation measured (right). Each data point for
the cell proliferation experiment represents the mean ± S.D.
(n = 9) of three separate experiments and each data point for the
3H-thymidine incorporation experiment represents the mean +
S.D. (n = 24) of three separate experiments and the data are
normalised relative to the untreated SFM control (100%). M=
Mibolerone.
1988; Wilding et al., 1989) in which other workers detected a
2-fold increase in the number of EGF receptors upon treat-
ment of LNCaP cell with androgens. However, the increases
observed were relatively small and neither group reported
any statistical analysis of their data. Therefore it remains
questionable whether the EGF receptor is up-regulated by
steroid hormones in LNCaP cells. Indeed, in the normal rat
prostate it was found that EGF receptor levels are down
regulated by androgens (Traish & Wotiz, 1987; St-Arnaud et
al., 1988). It is therefore not inconceivable that the interac-
tion between androgens and the EGF receptor in the normal
prostate may be lost, resulting in neoplastic growth.
Although DU145 cells possess large numbers of EGF
receptors, exogenous EGF had very little effect on the
growth and incorporation of 3H-thymidine in these cells. In
contrast, EGF elicited a substantial mitogenic response on
the androgen sensitive LNCaP cell line and this was dose-
dependent; A 2-fold increase in cell numbers and 3H-thymidine
incorporation into DNA was induced following treatment
with 3 nmol of EGF. A similar mitogenic effect by EGF was
also reported in earlier studies (Schuurmans et al., 1988;
Wilding et al., 1989).
In common with the findings on breast cancer cell lines
(Davidson et al., 1987) we observed a negative correlation
between the expression of the EGF receptor and the mito-
genic response to exogenous EGF. Like DU145 and LNCaP
cell lines, the presence of relatively low numbers of EGF
receptors on breast cancer cell lines was associated with the
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ability of the cell to manifest a mitogenic response to EGF,
whilst cells with higher EGF receptor numbers failed to
respond. Those cells which were stimulated to grow were
oestrogen-responsive whilst those which were only minimally
affected were oestrogen-unresponsive. It is not inconceivable
that the loss of steroid responsiveness of prostatic tumours
may be linked with a loss of dependence or a reduced
sensitivity to growth factors, possibly by autologous produc-
tion of growth factors. Indeed, we have previously shown
that DU145 cells produce EGF-like molecules (MacDonald
et al., 1990) which reduce the cells needs for exogenous
mitogens and thereby rendering the cells autostimulatory.
We might envisage that progression to an androgen inde-
pendent state may, in part, be due to a loss of androgen
regulation of growth factor production with cells producing
growth factors irrespective of the presence of androgens.
The authors wish to acknowledge the generous support of the
Association for International Cancer Research (AICR).
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